Abstracts tagged "Biologics"

Abstract Number: 2665 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice
Sebastian Unizony¹, Robert Spiera ², Jinglan Pei ³, Páris Sidiropoulos ³, Jennie Best ⁴ and John Stone ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Genentech, South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Approximately 50% of patients with giant cell arteritis (GCA) also have polymyalgia rheumatica (PMR) symptoms.1 The purpose of this study was to determine whether…
Abstract Number: 194 • 2019 ACR/ARP Annual Meeting
Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data
Fredrik Johansson¹, Jamie Collins ², Sara Gale ³, Hongshu Guan ⁴, Seoyoung C. Kim ⁵, Elena Losina ⁶, David Sontag ¹, Jacklyn Stratton ⁴, Huong Trinh ³, Jeffrey Greenberg ⁷ and Daniel Solomon ⁸, ¹MIT, Cambridge, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Genentech, San Francisco, CA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁸Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Predicting remission in rheumatoid arthritis (RA) is an important goal for tailoring therapy. Tocilizumab (TCZ) has been found in randomized controlled trials (RCT) to…
Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting
Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study
Philip Mease¹, Robert B.M. Landewé ², Proton Rahman ³, Hasan Tahir ⁴, Atul Singhal ⁵, Elke Böttcher ⁶, Sandra Navarra ⁷, Aimee Readie ⁸, Shephard Mpofu ⁹, Evie Maria Delicha ⁹, Luminita Pricop ⁸ and Désirée van der Heijde ¹⁰, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Southwest Rheumatology, Dallas, TX, ⁶Rheumazentrum Favoriten, Vienna, Austria, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…
Abstract Number: 2694 • 2019 ACR/ARP Annual Meeting
Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis
Rosemary Peterson¹, Rui Xiao ², Hannah Katcoff ¹, Brian Fisher ¹ and Pamela F. Weiss ¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: The effectiveness of IL-1 and IL-6 inhibitors as first-line therapy in patients with new-onset systemic JIA has led to the concept of a “window…
Abstract Number: 217 • 2019 ACR/ARP Annual Meeting
Fibromyalgia and Multiple Switching of Biologics in Spondylarthritis
Ahmed Negm¹, Nasir Elsidig ¹, Ahlam Al Marzooqi ¹, Noura Zamani ¹, Ayesha Hossaini ¹ and Jamal Al Saleh ¹, ¹Rheumatology Department, Dubai Hospital- Dubai Health Authority, Dubai, Dubai, United Arab Emirates
Background/Purpose: Fibromyalgia (FM) is a condition characterized by chronic widespread pain, tender points, fatigue and disturbed sleep rhythm. Some of these symptoms such as fatigue,…
Abstract Number: 1812 • 2019 ACR/ARP Annual Meeting
Delineating Early Response Trajectories to Biologics in Polyarticular Course Juvenile Idiopathic Arthritis
Lily SH Lim¹, Armend Lokku ², Sarah Ringold ³ and Eleanor M. Pullenayegum ⁴, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Toronto, TOronto, ON, Canada, ³Seattle Children's, Seattle, ⁴Child Health Evaluative Sciences, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
Background/Purpose: Most biologic trials in juvenile idiopathic arthritis (JIA) treat all participants with the biologic under study for 12 to 16 weeks before randomizing responders…
Abstract Number: 2707 • 2019 ACR/ARP Annual Meeting
Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Jordi Antón ⁴, Diego Viola ⁵, Bernard Lauwerys ⁶, Rubèn J Cuttica ⁷, Pierre Quartier ⁸, Elisabeth Gervais ⁹, Alexandre Belot ¹⁰, Kirsten Minden ¹¹, Thomas Lutz ¹², Rolando Cimaz ¹³, Mahmood M. T. M. Ally ¹⁴, Riana van Zyl ¹⁵, Inmaculada Calvo Penadés ¹⁶, Joe Zhuo ¹⁷, Robert Wong ¹⁸, Marleen Nys ¹⁹, Yedid Elbez ²⁰, Alberto Martini ²¹, Daniel J. Lovell ²² and Nicolino Ruperto ²³, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Hospital Sant Joan de Déu, Barcelona, Spain, ⁵CAICI Institute, Rosario City, Santa Fe State, Argentina, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁸Necker Hospital, Paris, France, ⁹CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁰Centre Hospitalier Universitaire de Lyon, Lyon, France, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²Heidelberg University Hospital, Heidelberg, Germany, ¹³Meyer Children's Hospital in Florence, Florence, Italy, ¹⁴University of Pretoria, Pretoria, South Africa, ¹⁵University of the Free State, Bloemfontein, South Africa, ¹⁶Hospital Univ. La Fe, Valencia, Spain, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Princeton, ¹⁹Bristol-Myers Squibb, Braine L’Alleud, Belgium, ²⁰Excelya, Boulogne-Billancourt, France, ²¹IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ²²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ²³Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Efficacy of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label, Phase III international study (NCT01844518).1 Pediatric patient-reported outcomes…
Abstract Number: 249 • 2019 ACR/ARP Annual Meeting
Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Damemarie Paul ¹, Xue Han², Irina Yermilov ³, Sarah Gibbs ³ and Michael Broder ³, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²Bristol-Myers Squibb Company, Princeton, NJ, ³Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Abatacept is recommended as first-line biologic therapy in adult patients with moderate to severe RA. We aimed to assess real-world 1-year treatment persistence in…
Abstract Number: 1815 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials
Nicolino Ruperto¹, Daniel J. Lovell ², John Bohnsack ³, Johannes Breedt ⁴, Michel Fischbach ⁵, Thomas Lutz ⁶, Kirsten Minden ⁷, Tatiana Miraval ⁸, Mahmood M. T. M. Ally ⁹, Nadina Rubio-Pérez ¹⁰, Elisabeth Gervais ¹¹, Riana van Zyl ¹², Robert Wong ¹³, Marleen Nys ¹⁴, Alberto Martini ¹⁵ and Hermine Brunner ¹⁶, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa, ⁵Pédiatrie 1, CHU Hautepierre, Strasbourg, France, ⁶Heidelberg University Hospital, Heidelberg, Germany, ⁷German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ⁸Clínica San Gabriel, Lima, Peru, ⁹University of Pretoria, Pretoria, South Africa, ¹⁰University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ¹¹CHU de Poitiers, Rheumatology, Poitiers, France, ¹²University of the Free State, Bloemfontein, South Africa, ¹³Bristol-Myers Squibb, Princeton, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁶Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: In EU, abatacept (ABA) with MTX is approved in patients (pts) with polyarticular-course JIA (pJIA), as young as 2 years (SC) and 6 years…
Abstract Number: 2708 • 2019 ACR/ARP Annual Meeting
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Alberto Berman ⁴, Inmaculada Calvo Penadés ⁵, Jordi Antón ⁶, Francisco Ávila-Zapata ⁷, Rubèn J Cuttica ⁸, Gerd Horneff ⁹, Robert Wong ¹⁰, Mehmooda Shaikh ¹¹, Johanna Mora ¹¹, Marleen Nys ¹², Daniel J. Lovell ¹³, Alberto Martini ¹⁴ and Nicolino Ruperto ¹⁵, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital Sant Joan de Déu, Barcelona, Spain, ⁷Star Medica Hospital, Merida, Yucatán, Mexico, ⁸Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Bristol-Myers Squibb, Princeton, NJ, ¹²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹⁴IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…
Abstract Number: 259 • 2019 ACR/ARP Annual Meeting
Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty
Joseph Tkacz ¹, Ervant Maksabedian², Philip Chan ¹, Brendan Limone ¹, Alexis Ogdie ³, Elaine Karis ⁴ and Bradley Stolshek ², ¹IBM Watson, Bethesda, MD, ²Amgen Inc., Thousand Oaks, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Amgen Inc, Thousand Oaks, CA
Background/Purpose: The clinical heterogeneity of psoriatic arthritis (PsA) presents a variety of diagnostic and treatment challenges, which may be reflected in the way different health…
Abstract Number: 1818 • 2019 ACR/ARP Annual Meeting
Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study
Laura Coates¹, Sreekumar Pillai ², Lu Zhang ², David Adams ², Lisa Kerr ², Maja Hojnik ², Gaia Gallo ², Ivo Valter ³, Hasan Tahir ⁴, Vinod Chandran ⁵, Philip Mease ⁶ and Arthur Kavanaugh ⁷, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³Center for Clinical and Basic Research, Tallinn, Estonia, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Division of Rheumatology, University of Toronto, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that may lead to serious disability if not appropriately treated. Data on the effect of treatment…
Abstract Number: 2711 • 2019 ACR/ARP Annual Meeting
Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Daniah Basodan¹, Kathleen M Andersen ², Xintong Li ³, Jeffrey Curtis ⁴ and G. Caleb Alexander ⁵, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD
Background/Purpose: In recent years, juvenile idiopathic arthritis (JIA) treatment options have expanded to include biologics such as tumor necrosis factor inhibitors (TNFi) and non-TNF inhibitors…
Abstract Number: 526 • 2019 ACR/ARP Annual Meeting
Factors Influencing Discontinuation in Long-term RA Treatment
Madison Grinnell¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of Nebraska College of Medicine, OMAHA, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While medication persistence can act as a substitute metric for effectiveness, few studies have examined real-world patterns of bDMARD persistence by line of treatment…
Abstract Number: 1836 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
Robert Spiera¹, Sebastian Unizony ², Min Bao ³, Yves Luder ⁴, Páris Sidiropoulos ³, Jian Han ³, Jinglan Pei ³ and John Stone ², ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Genentech, South San Francisco, CA, ⁴F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: GiACTA, a randomized, double-blind, placebo (PBO)–controlled study, demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA).1 Growing evidence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].